The SURMOUNT trials used weekly tirzepatide dosing exclusively and showed average weight loss of 22.5% at the highest dose
Weight-based considerations for sublingual dosing Body weight affects sublingual tirzepatide dosing just as it affects injectable dosing, possibly more so
If the impurities are confirmed by independent laboratories, the case for separating B12 from tirzepatide becomes overwhelming
A qualified healthcare provider should establish baseline symptoms (bowel habits, reflux, abdominal pain), review medications that interact with bile (e.g., fat-soluble vitamins, certain antibiotics), and schedule follow-up assessments at 2-4 weeks post-initiation
This medication is administered via subcutaneous injection, meaning it must be delivered into the fatty tissue layer beneath the skin but above the muscle